Applying Pharmacometrics to Precision Dosing in the Lifecycle of Long-acting Injectable Products: Drug Development, Regulatory Approval & Clinical Practice

QUANTITATIVE TRACK
Offers both CME & CPE Credit
UAN #JA4008220-0000-20-026-H03-P
ACPE – 2 CONTACT HOURS/KNOWLEDGE-BASED

CO-CHAIRS:
Hong Lu, PhD, Scientific Director, Takeda Pharmaceuticals USA Inc
Lanyan (Lucy) Fang, PhD, Associate Director, Quantitative Methods & Modeling, Research & Standards, Generic Drugs, Ctr for Drug Evaluation & Research, US Food & Drug Administration

TARGET AUDIENCE:
This Symposium will be useful for drug developers, regulators, physicians and pharmacists.

GOALS & OBJECTIVES:
Following the completion of this activity, the learner will be able to:
1. Describe the complex pharmacokinetic characteristics of long-acting injectable products that lead to both challenges and opportunities in applying model-informed approaches in development, regulatory approval and clinical dosing practice;
2. Learn a novel quantitative framework for identifying the dose and formulation that maximize the benefit-risk ratio using in vitro/in vivo correlation. Apply the modeling strategy to other sustained-release products;
3. Describe the need and approaches for individualized dosing of antipsychotics and discuss the challenges of translating them to a product or tool adopted by healthcare providers in clinical practice;
4. Describe how receptor pharmacology, pharmacokinetics and pharmacodynamics of antipsychotics are combined to optimize clinical outcomes of antipsychotics and apply the proposed thought flow to other disease areas with target-mediated therapy.

Introduction
Lanyan (Lucy) Fang, PhD, Associate Director, Quantitative Methods & Modeling, Research & Standards, Generic Drugs, Ctr for Drug Evaluation & Research, US Food & Drug Administration

Clinical Application of Pharmacometrics in Dosing Management of Long-acting Injectable (LAI) Antipsychotics
Hong Lu, PhD, Scientific Director, Takeda Pharmaceuticals USA Inc

Convolution-based Approach for Modeling, Establishing In Vitro/In Vivo Correlation & Optimizing the In Vivo Drug Release Properties of LAI Products
Roberto Gomeni, PhD, President, PharmacoMetrica & Adjunct Professor, Pharmacotherapy & Experimental Therapeutics, Univ of North Carolina Eshelman School of Pharmacy

Generating Model-integrated Evidence for Developing & Approving Complex Generic LAI Products
Liang Zhao, PhD, Director, Quantitative Methods & Modeling, Research & Standards, Generic Drugs, Ctr for Drug Evaluation & Research, US Food & Drug Administration

Role of Pharmacometrics in Guiding Clinical Practice Dosing of LAI Products
Yaning Wang, PhD, Director, Pharmacometrics, Clinical Pharmacology, US Food & Drug Administration

Faculty Panel Discussion, Questions & Answers, Learner Feedback & Evaluation